Your session is about to expire
← Back to Search
Atorvastatin for Preventing Dementia (PREVENTABLE Trial)
PREVENTABLE Trial Summary
This trial will show whether atorvastatin can prevent death, dementia, and disability in older adults without cardiovascular disease or dementia.
PREVENTABLE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowPREVENTABLE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.PREVENTABLE Trial Design
Find a Location
Logistics
Other reimbursement is provided
Other forms of reimbursement are provided for this trial.
Who is running the clinical trial?
Media Library
- I have been diagnosed with or show clear signs of dementia.I am unable to speak.I regularly take colchicine, verapamil, or more than 240mg/day of diltiazem.I have an active liver condition.I need help with daily activities like bathing or dressing, but not with using the bathroom.My doctor says I can't take 40 mg of atorvastatin.I live in my own home or with family.I have been taking statin medication for the past year or for more than 5 years.You have significant vision loss that may interfere with cognitive testing.You have had a bad reaction or side effects to taking statins.My primary language is either English or Spanish.I am 75 years old or older.I am 75 years old or older.I have had a heart attack, stroke, heart surgery, or need medication to prevent heart disease.I was hospitalized for heart failure in the last year.I have severe hearing loss that makes phone calls difficult.
- Group 1: Placebo
- Group 2: atorvastatin 40mg
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Screening: It may take up to 0 Weeks to process to see if you qualify in this trial.
- Treatment: You will receive the treatment for 60 Months
- Follow Ups: You may be asked to continue sharing information regarding the trial for 0 Months after you stop receiving the treatment.
Frequently Asked Questions
What health conditions is Atorvastatin 40 Mg Oral Tablet most often utilized for?
"Atorvastatin 40 Mg Oral Tablet is an ideal remedy for lipidemias, postoperative thromboembolism and anginal pain."
How many participants are the maximum capacity of this research endeavor?
"In order to have the desired impact, this clinical trial requires 20 thousand patients who meet eligibility criteria. Patients in Asheville VA-Charles George VA Medical Center (Asheville, NC) and Cincinnati VA Medical Center (Cincinnati, OH) are both invited to take part."
How many locations are conducting this investigation?
"This trial is presently recruiting patients at a total of 74 distinct sites, including the Asheville VA-Charles George VA Medical Center, Cincinnati VA Medical Centre and Duke University in Durham."
Have there been any past research projects that have focused on Atorvastatin 40 Mg Oral Tablet?
"OHSU Hospital first tested Atorvastatin 40 Mg Oral Tablet in 2005 and since then, 531 trials have been completed. Presently there are 70 active clinical trials taking place primarily in Asheville, North carolina."
Has the Atorvastatin 40 Mg Oral Tablet been ratified by the federal regulatory agency?
"There is ample evidence of Atorvastatin 40 Mg Oral Tablet's safety, so it scored a 3 on our team's evaluation scale. This medication has already been approved for use in Phase 4 clinical trials."
Has this innovative research ever been attempted before?
"Since 2005, research has been conducted on Atorvastatin 40 Mg Oral Tablet. 80 patients were involved in the initial study sponsored by Merck Sharp & Dohme LLC and this drug received its final approval from phase 4 trials. Currently, 70 studies are live for this medication across 162 cities and 28 countries worldwide."
Are there any opportunities presently available to participate in this experiment?
"Affirmative. Per the details available on clinicaltrials.gov, this healthcare trial is presently recruiting participants and was first announced to the public on September 1st 2020. 20000 individuals are needed for enrolment across 74 distinct medical sites."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- University of Chicago: < 24 hours
- Rush University Medical Center: < 48 hours
Average response time
- < 2 Days
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger